-
Subject Areas on Research
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
-
Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.
-
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
-
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.
-
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
-
Critical role for mouse marginal zone B cells in PF4/heparin antibody production.
-
Cryoprecipitate therapy.
-
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
-
Domino liver transplantation in maple syrup urine disease: a case report and review of the literature.
-
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.
-
Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation.
-
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.
-
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
-
Factor X deficiency and pregnancy: preconception counselling and therapeutic options.
-
Factor concentrates for perioperative bleeding: old drugs with new approaches.
-
Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis.
-
Heparin-induced decrease in circulating antithrombin-III.
-
Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
-
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
-
Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
-
Obstetric hemorrhage.
-
Postpartum hemorrhage: when uterotonics and sutures fail.
-
Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study.
-
Progressive improvement in wound healing with increased therapy in haemophilia B mice.
-
Reversal agents for non-vitamin K antagonist oral anticoagulants.
-
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
-
Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations.
-
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
-
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.